293 related articles for article (PubMed ID: 30663923)
1. Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections.
White BP; Patel S; Tsui J; Chastain DB
Infect Dis (Lond); 2019 Mar; 51(3):161-167. PubMed ID: 30663923
[TBL] [Abstract][Full Text] [Related]
2. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
3. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
4. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
5. Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: A retrospective cohort study.
Gao S; Yan R; Zhang S; Li L; Zhang R; Fan J; Qin J; Peng Y; Wan D; Cao W; Bian Z
J Glob Antimicrob Resist; 2024 Mar; 36():96-104. PubMed ID: 38128727
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
[TBL] [Abstract][Full Text] [Related]
7. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Chastain DB; White BP; Cretella DA; Bland CM
Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
9. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
Trecarichi EM; Tumbarello M
Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
Zilberberg MD; Shorr AF
J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?
Perez F; El Chakhtoura NG; Papp-Wallace KM; Wilson BM; Bonomo RA
Expert Opin Pharmacother; 2016; 17(6):761-81. PubMed ID: 26799840
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics of carbapenem-resistant
Sun Y; Zheng H; Zhang JL; Yu LX; Wang B; Gao W; Cai JZ; Liu YH
Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):640-645. PubMed ID: 32842384
[No Abstract] [Full Text] [Related]
14. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.
Chiotos K; Tamma PD; Flett KB; Naumann M; Karandikar MV; Bilker WB; Zaoutis T; Han JH
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971864
[TBL] [Abstract][Full Text] [Related]
15. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children.
Ara-Montojo MF; Escosa-García L; Alguacil-Guillén M; Seara N; Zozaya C; Plaza D; Schuffelmann-Gutiérrez C; de la Vega Á; Fernández-Camblor C; Ramos-Boluda E; Romero-Gómez MP; Ruiz-Carrascoso G; Losantos-García I; Mellado-Peña MJ; Gómez-Gil R
J Antimicrob Chemother; 2021 Jan; 76(1):220-225. PubMed ID: 33038895
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
17. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort.
Rigatto MH; Ramos F; Barros A; Pedroso S; Guasso I; Gonçalves L; Bergo P; Zavascki AP
J Antimicrob Chemother; 2022 Oct; 77(11):3118-3125. PubMed ID: 36048569
[TBL] [Abstract][Full Text] [Related]
18. Management of carbapenem-resistant Enterobacteriaceae infections.
Durante-Mangoni E; Andini R; Zampino R
Clin Microbiol Infect; 2019 Aug; 25(8):943-950. PubMed ID: 31004767
[TBL] [Abstract][Full Text] [Related]
19. Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?
Metan G; Akova M
Curr Opin Infect Dis; 2016 Dec; 29(6):555-560. PubMed ID: 27584588
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem-resistant
Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
Front Public Health; 2022; 10():983174. PubMed ID: 36091556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
